Rein Therapeutics Inc.
RNTXHealthcare|Biotechnology|US
$0.61
+0.00 (+0.28%)
Cash / Share
$1.34
Financials
Financial Snapshot
Market Cap
$52.9M
Enterprise Value
$44.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$49.8M
Cash & Investments
$40.6M
Net Cash
$40.6M
Free Cash Flow (TTM)
-$18.8M
Operating CF (TTM)
-$18.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$40.6M
Quarterly Burn
$4.7M
Monthly Burn
$1.6M
Est. Runway
~8.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $13.8M | $45.9M | $21.2M | $17.3M | $12.9M | $3.2M | $40.6M | |
| Operating Cash Flow | -$20.5M | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M | -$18.8M | |
| Free Cash Flow | -$20.5M | -$23.9M | -$24.9M | -$19.8M | -$22.3M | -$19.4M | -$18.8M | |
| Capital Expenditure | -$5.0K | -$157.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $15.8M | $55.7M | $0.00 | $15.8M | $17.8M | $9.8M | $56.8M |
R&D Spending
R&D (TTM)
$10.4M
R&D Intensity
—
R&D Growth vs Prior
-5.8%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $11.2K | $17.0K | $18.0K | $4.0K | $14.2M | $11.0M | $10.4M | |
| SG&A | $9.3K | $9.6K | $9.7K | $11.4K | $13.9M | $10.9M | $10.4M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0K | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | |
| R&D | $11.2K | $17.0K | $18.0K | $4.0K | $14.2M | $11.0M | $10.4M | |
| SG&A | $9.3K | $9.6K | $9.7K | $11.4K | $13.9M | $10.9M | $10.4M | |
| Operating Income | -$20.5K | -$26.6K | -$27.6K | -$16.3K | -$65.1M | -$21.9M | -$20.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$21.2K | -$26.2K | -$27.3K | -$15.7K | -$64.3M | -$50.6M | -$50.5M | |
| Net Income | -$21.2K | -$26.2K | -$27.3K | -$15.7K | -$62.9M | -$49.9M | -$49.8M | |
| EPS (Diluted) | -0.00 | -5.89 | -6.02 | -3.42 | -3.51 | -1.96 | -1.83 | |
| EBITDA | $142.5K | $94.8K | $141.7K | $103.7K | -$28.0M | -$50.6M | -$21.0M | |
| Shares Out. (M) | 17.43 | 4.44 | 4.54 | 4.60 | 17.94 | 25.44 | 30.35 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.0M | $3.6M | $5.2M | $17.3M | $12.9M | $3.2M | $8.5M | |
| Short-Term Investments | $6.8M | $42.3M | $16.0M | $0.00 | $0.00 | $0.00 | $32.1M | |
| Total Current Assets | $16.3M | $48.2M | $21.9M | $18.3M | $13.7M | $4.3M | $41.5M | |
| Total Assets | $16.3M | $48.5M | $22.0M | $106.0M | $69.2M | $24.2M | $66.0M | |
| Total Current Liabilities | $4.0M | $4.5M | $3.4M | $4.4M | $5.7M | $6.2M | $9.7M | |
| Long-Term Debt | $219.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $4.2M | $4.6M | $3.4M | $99.1M | $14.8M | $7.2M | $55.8M | |
| Stockholders' Equity | $12.2M | $43.9M | $18.6M | $6.9M | $54.4M | $16.9M | $10.2M | |
| Retained Earnings | -$219.3M | -$245.5M | -$272.8M | -$288.5M | -$351.4M | -$401.3M | -$413.5M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.5M | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M | -$18.8M | |
| Capital Expenditure | -$5.0K | -$157.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$20.5M | -$23.9M | -$24.9M | -$19.8M | -$22.3M | -$19.4M | -$18.8M | |
| Investing Cash Flow | $6.4M | -$35.9M | $26.5M | $16.2M | $0.00 | $0.00 | -$35.1M | |
| Financing Cash Flow | $15.8M | $55.7M | $0.00 | $15.8M | $17.8M | $9.8M | $56.8M | |
| Issuance of Stock | $15.4M | $55.6M | $0.00 | $0.00 | $10.6M | $9.8M | $57.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $387.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.2M | |
| Stock Based Comp. | $1.9M | $2.3M | $2.1M | $1.2M | $1.1M | $2.2M | $2.0M | |
| Net Change in Cash | $1.7M | -$4.0M | $1.6M | $12.1M | -$4.5M | -$9.7M | $2.8M |
Dilution Tracker
Shares outstanding grew 46.0% over 5 years — significant dilution
Shares Outstanding
86M
5-Year Share Growth
+46.0%
Stock Issuance (TTM)
$57.8M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 17.43 | 4.44 | 4.54 | 4.60 | 17.94 | 25.44 | 30.35 | |
| Change vs Prior % | — | -74.5% | 2.2% | 1.3% | 290.1% | 41.8% | 19.3% | |
| Stock Issuance | $15.4M | $55.6M | $0.00 | $0.00 | $10.6M | $9.8M | $57.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.9M | $2.3M | $2.1M | $1.2M | $1.1M | $2.2M | $2.0M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | -0.2% | -0.1% | -0.1% | -0.2% | -115.6% | -294.8% | -234.5% | |
| ROA % | -0.1% | -0.1% | -0.1% | -0.0% | -90.8% | -206.4% | -75.4% | |
| ROIC % | -0.2% | -0.1% | -0.1% | -0.0% | -100.1% | -120.3% | -36.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -29.8% | -3.9% | 41.1% | -399949.2% | 66.3% | |
| Net Income | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -23.7% | -4.5% | 42.4% | -399614.0% | 20.7% | |
| EPS (Diluted) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -490733.3% | -2.2% | 43.2% | -2.6% | 44.2% | |
| Operating Cash Flow | -28.2% | -36.7% | -36.0% | 5.2% | 22.7% | -16.0% | -4.7% | 20.3% | -12.5% | 13.1% | |
| Free Cash Flow | -27.2% | -37.7% | -56.5% | 17.7% | 23.1% | -16.7% | -4.0% | 20.3% | -12.5% | 13.1% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 52.3% | 5.6% | -77.8% | 356903.3% | -22.6% | |
| SG&A Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.9% | 0.9% | 17.3% | 121974.5% | -21.4% | |
| Total Assets | 270.7% | 139.3% | -42.5% | -12.7% | -38.3% | 196.7% | -54.6% | 381.7% | -34.7% | -65.1% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1317.1% | -58.5% | -63.5% | 102.4% | -78.1% | |
| Debt | 0.0% | 0.0% | 0.0% | -5.8% | -92.3% | -58.1% | -79.6% | 45.5% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -74.5% | 2.2% | 1.3% | 290.1% | 41.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.83
10Y Low / Med / High0.21 / 1.42 / 3.04
EV/EBITDAAt Loss
10Y Low / Med / High31.49 / 63.00 / 212.57
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$1.34
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1766.67 | -0.36 | -0.35 | -0.62 | -0.66 | -0.59 | -0.34 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 3.04 | 0.21 | 0.52 | 1.42 | 0.76 | 1.74 | 1.83 | |
| EV/EBITDA | 212.57 | 63.00 | 31.49 | -72.52 | -1.01 | -0.52 | -2.11 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-8.71
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $69.8M | $127.7M | $0.00 |
| Net Income | -$11.7M | -$11.8M | -$15.1M |
| EPS | $-0.46 | $-0.47 | $-0.59 |
| # Analysts (EPS) | 1 | 1 | 2 |